Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021417 | 0.78 | KDM4E (0.52) | NCF1PNMTDPP4LOXL2CYP2C19 | |
| SCHEMBL30332127 | 0.78 | KDM4E (0.52) | NCF1PNMTDPP4LOXL2CYP2C19 | |
| SCHEMBL2463222 | 0.77 | IDO1 (0.56) | LOXL2CYP2C19MAPTTSHRCYP2A6 | |
| SCHEMBL16793052 | 0.74 | TPH1 (0.42) | NCF1CYP2C19CYP2A6 | |
| SCHEMBL4927896 | 0.73 | ALDH1A1 (0.53) | MAPTTSHRKDM4ENOTUM | |
| SCHEMBL9435417 | 0.71 | GAA (0.60) | MAPTTSHRKDM4EGAANOTUM | |
| SCHEMBL16793221 | 0.69 | NOTUM (0.42) | NCF1PNMTLOXL2CYP2C19NOTUM | |
| SCHEMBL4611825 | 0.69 | LMNA (0.43) | NCF1PNMTCYP2A6KDM4E | |
| SCHEMBL30332360 | 0.69 | NOTUM (0.42) | NCF1PNMTLOXL2CYP2C19NOTUM | |
| SCHEMBL30332313 | 0.69 | LMNA (0.43) | NCF1PNMTCYP2A6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-7026324-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097730-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| EP-1359913-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002064140-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097730-A1 | Thrombin inhibitors | F3, F2, SERPINC1 | NCF1 240/4885PNMT 4379/4885DPP4 427/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | NCF1 630/4885PNMT 2004/4885DPP4 241/4885 |
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | NCF1 138/4885PNMT 2668/4885DPP4 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.